Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

BACKGROUND: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibod...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Main Authors: Borghi, Maria Orietta, Beltagy, Asmaa, Garrafa, Emirena, Curreli, Daniele, Cecchini, Germana, Bodio, Caterina, Grossi, Claudia, Blengino, Simonetta, Tincani, Angela, Franceschini, Franco, Andreoli, Laura, Lazzaroni, Maria Grazia, Piantoni, Silvia, Masneri, Stefania, Crisafulli, Francesca, Brugnoni, Duilio, Muiesan, Maria Lorenza, Salvetti, Massimo, Parati, Gianfranco, Torresani, Erminio, Mahler, Michael, Heilbron, Francesca, Pregnolato, Francesca, Pengo, Martino, Tedesco, Francesco, Pozzi, Nicola, Meroni, Pier Luigi
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7593765/
https://ncbi.nlm.nih.gov/pubmed/33178218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.584241
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares